<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39435386</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-2360</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in pediatrics</Title><ISOAbbreviation>Front Pediatr</ISOAbbreviation></Journal><ArticleTitle>Children with sickle cell disease: are they protected from serious COVID-19?</ArticleTitle><Pagination><StartPage>1337377</StartPage><MedlinePgn>1337377</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1337377</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fped.2024.1337377</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">COVID-19, the pandemic that hit the world in 2020, resulted in millions of deaths, with the elderly and adults succumbing to the disease more often than children. However, the presence of underlying morbidities increased the risk of death. Sickle cell disease (SCD) was previously classified as a major risk factor for severe COVID-19 disease. However, presently, there are only a limited number of studies that identify the clinical course of children with SCD and COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We conducted a retrospective observational study on children with SCD admitted due to COVID-19 at three different institutions in Saudi Arabia between March 2020 and March 2022. We studied the demographic and clinical characteristics of patients admitted to the hospital.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Seventy-six patients with SCD had PCR-confirmed SARS-CoV-2 during the study period; 50.0% of our patient population were children (6-12 years old). Gender was evenly distributed, with 53.9% girls and 46.1% boys. Symptoms more commonly related to the COVID-19 infection included fever, cough, malaise, and vomiting. Chest x-ray findings revealed mild and non-specific symptoms only in approximately one-third (28) of the included children. The most common symptoms associated with SCD were vaso-occlusive crisis (47.4%) and abdominal pain (11.8%). The overall general appearance of most of the patients was reassuring. The median length of hospital stay was 4.2 ± 2.7 days. The mean white blood cell count was 11.4 ± 5.2 × 10<sup>9</sup>/L, and the mean hemoglobin level was 8.3 ± 1.5 g/dl. Despite the fact that higher levels of mean D-dimer, lactate dehydrogenase, and ferritin were reported in these patients, the clinical outcome was not affected. All recruited patients received hydroxyurea as maintenance therapy. The outcome of our study was reassuring, with no significant morbidity or mortality observed among the recruited patients.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Despite SCD being a chronic disease with known specific complications, there has been a claim that COVID-19 infection adds further risk. The results of this study suggest that the overall outcome of COVID-19 was favorable, with no reported mortality. Further research is needed to understand the factors that contributed to this favorable outcome. In children with SCD, it is still questionable whether hydroxyurea is one of the protective factors against severe COVID-19. Validation through large-scale research is recommended.</AbstractText><CopyrightInformation>© 2024 Shahin, Aldeeb, Alsulami, Tammas, Albatniji, Almanea, Zayed, Alabbas, Alzahrani, Bin Ali, Elyamany, Almaghrabi and Elfaraidi.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shahin</LastName><ForeName>Walaa Aboulkasem</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Specialized Children's Hospital, Cairo University, Cairo, Egypt.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aldeeb</LastName><ForeName>Hayam</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alsulami</LastName><ForeName>Majed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tammas</LastName><ForeName>Abdullah</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albatniji</LastName><ForeName>Fatma</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almanea</LastName><ForeName>Aljawhara</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hematology Division, Department of Pediatrics, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zayed</LastName><ForeName>Abdalla Mohamed</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, King Fahad Medical City, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alabbas</LastName><ForeName>Fahad</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alzahrani</LastName><ForeName>Azzah</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bin Ali</LastName><ForeName>Tahani</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elyamany</LastName><ForeName>Ghaleb</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Central Military Laboratory and Blood Bank, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almaghrabi</LastName><ForeName>Rana Hassan</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elfaraidi</LastName><ForeName>Huda</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Pediatr</MedlineTA><NlmUniqueID>101615492</NlmUniqueID><ISSNLinking>2296-2360</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Saudi Arabia</Keyword><Keyword MajorTopicYN="N">hydroxyurea</Keyword><Keyword MajorTopicYN="N">pediatrics</Keyword><Keyword MajorTopicYN="N">sickle cell</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>10</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>10</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>4</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39435386</ArticleId><ArticleId IdType="pmc">PMC11491405</ArticleId><ArticleId IdType="doi">10.3389/fped.2024.1337377</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO Dashboard. WHO COVID-19 Dashboard. Geneva: World Health Organization;  (2020). Available online at:
https://covid19.who.int/
(accessed December 18, 2022).</Citation></Reference><Reference><Citation>Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. (2020) 382(13):1199–207. 10.1056/NEJMoa2001316</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001316</ArticleId><ArticleId IdType="pmc">PMC7121484</ArticleId><ArticleId IdType="pubmed">31995857</ArticleId></ArticleIdList></Reference><Reference><Citation>Leeb RT, Price S, Sliwa S, Kimball A, Szucs L, Caruso E, et al. 
MMWR, COVID-19 trends among school-aged children—United States, March 1–September 19, 2020 [Internet]. Available online at:
https://www.cdc.gov/mmwr/volumes/69/wr/mm695152a5.htm?s_cid=mm695152a5_w (accessed December 02, 2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7537558</ArticleId><ArticleId IdType="pubmed">33001869</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff RC, Campbell AP, Taylor CA, Chai SJ, Kawasaki B, Meek J, et al. Risk factors for severe COVID-19 in children. Pediatrics. (2022) 149(1):e2021053418. 10.1542/peds.2021-053418</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2021-053418</ArticleId><ArticleId IdType="pmc">PMC9213563</ArticleId><ArticleId IdType="pubmed">34935038</ArticleId></ArticleIdList></Reference><Reference><Citation>DeBiasi RL, Song X, Delaney M, Bell M, Smith K, Pershad J, et al. Severe coronavirus disease-2019 in children and young adults in the Washington, DC, Metropolitan region. J Pediatr. (2020) 223:199–203.e1. 10.1016/j.jpeds.2020.05.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2020.05.007</ArticleId><ArticleId IdType="pmc">PMC7217783</ArticleId><ArticleId IdType="pubmed">32405091</ArticleId></ArticleIdList></Reference><Reference><Citation>Panepinto JA, Brandow A, Mucalo L, Yusuf F, Sing A, Taylor B, et al. Coronavirus disease among persons with sickle cell disease, United States, March 20–May 21, 2020. Emerg Infect Dis. (2020) 26(10):2473–6. 10.3201/eid2610.202792</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2610.202792</ArticleId><ArticleId IdType="pmc">PMC7510702</ArticleId><ArticleId IdType="pubmed">32639228</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucalo L, Brandow AM, Dasgupta M, Mason SF, Simpson PM, Singh A, et al. Comorbidities are risk factors for hospitalization and serious COVID-19 illness in children and adults with sickle cell disease. Blood Adv. (2021) 5(13):2717–24. 10.1182/bloodadvances.2021004288</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2021004288</ArticleId><ArticleId IdType="pmc">PMC8248962</ArticleId><ArticleId IdType="pubmed">34196678</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkindi S, Elsadek RA, Al-Madhani A, Al-Musalhi M, AlKindi SY, Al-Khadouri G, et al. Impact of COVID-19 on vasooclusive crisis in patients with sickle cell anemia. Int J Infect Dis. (2021) 106:128–33. 10.1016/j.ijid.2021.03.044</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.03.044</ArticleId><ArticleId IdType="pmc">PMC7962915</ArticleId><ArticleId IdType="pubmed">33741487</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelon I, Vilbert M, Pinheiro IS, Costa IL, Lorea CF, Castonguay M, et al. COVID-19 outcomes in patients with sickle cell disease and sickle cell trait compared with individuals without sickle cell disease or trait: a systematic review and meta-analysis. EClinicalMedicine. (2023) 66:102330. 10.1016/j.eclinm.2023.102330</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.102330</ArticleId><ArticleId IdType="pmc">PMC10755716</ArticleId><ArticleId IdType="pubmed">38162948</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Qurashi MM, El-Mouzan MI, Al-Herbish AS, Al-Salloum AA, Al-Omar AA. The prevalence of sickle cell disease in Saudi children and adolescents. A community-based survey. Saudi Med J. (2008) 29(10):1480–3.</Citation><ArticleIdList><ArticleId IdType="pubmed">18946577</ArticleId></ArticleIdList></Reference><Reference><Citation>Jastaniah W. Epidemiology of sickle cell disease in Saudi Arabia. Ann Saudi Med. (2011) 31(3):289–93. 10.4103/0256-4947.81540</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0256-4947.81540</ArticleId><ArticleId IdType="pmc">PMC3119971</ArticleId><ArticleId IdType="pubmed">21623060</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoogenboom WS, Alamuri TT, McMahon DM, Balanchivadze M, Dabak V, Mitchel WB, et al. Clinical outcomes of COVID-19 in patients with sickle cell disease and sickle cell trait: a critical appraisal of the literature. Blood Rev. (2022) 53:100911. 10.1016/j.blre.2021.100911</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.blre.2021.100911</ArticleId><ArticleId IdType="pmc">PMC8605823</ArticleId><ArticleId IdType="pubmed">34838342</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundd P, Gladwin MT, Novelli EM. Pathophysiology of sickle cell disease. Annu Rev Pathol. (2019) 14:263–92. 10.1146/annurev-pathmechdis-012418-012838</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pathmechdis-012418-012838</ArticleId><ArticleId IdType="pmc">PMC7053558</ArticleId><ArticleId IdType="pubmed">30332562</ArticleId></ArticleIdList></Reference><Reference><Citation>Inusa BPD, Hsu LL, Kohli N, Patel A, Ominu-Evbota K, Anie KA, et al. Sickle cell disease-genetics, pathophysiology, clinical presentation and treatment. Int J Neonatal Screen. (2019) 5(2):20. 10.3390/ijns5020020</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijns5020020</ArticleId><ArticleId IdType="pmc">PMC7510211</ArticleId><ArticleId IdType="pubmed">33072979</ArticleId></ArticleIdList></Reference><Reference><Citation>Kashari O, Alghamdi B, Al-Hebshi A, Asiri A, Fallatah E, Alshehri F, et al. COVID-19 in Saudi patients with sickle cell disease: a retrospective multi-center study. Cureus. (2021) 13(8):e17238. 10.7759/cureus.17238</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.17238</ArticleId><ArticleId IdType="pmc">PMC8369254</ArticleId><ArticleId IdType="pubmed">34422504</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahin W, Rabie W, Alyossof O, Alasiri M, Alfaki M, Mahmoud E, et al. COVID-19 in children ranging from asymptomatic to multi-system inflammatory disease: a single-center study. Saudi Med J. (2021) 42(3):299–305. 10.15537/smj.2021.42.3.20200625</Citation><ArticleIdList><ArticleId IdType="doi">10.15537/smj.2021.42.3.20200625</ArticleId><ArticleId IdType="pmc">PMC7989263</ArticleId><ArticleId IdType="pubmed">33632909</ArticleId></ArticleIdList></Reference><Reference><Citation>Heart N, Institute B. Evidence-based management of sickle cell disease: expert panel. (2014). Available online at:
https://www.nhlbi.nih.gov/health-topics/evidence-based-management-sickle-cell-disease (accessed May 10, 2024).</Citation></Reference><Reference><Citation>Assiri A, Al-Tawfiq JA, Alkhalifa M, Al Duhailan H, Al Qahtani S, Dawas RA, et al. Launching COVID-19 vaccination in Saudi Arabia: lessons learned, and the way forward. Travel Med Infect Dis. (2021) 43:102119. 10.1016/j.tmaid.2021.102119</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmaid.2021.102119</ArticleId><ArticleId IdType="pmc">PMC8197679</ArticleId><ArticleId IdType="pubmed">34133965</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. (2020) 109(6):1088–95. 10.1111/apa.15270</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apa.15270</ArticleId><ArticleId IdType="pmc">PMC7228328</ArticleId><ArticleId IdType="pubmed">32202343</ArticleId></ArticleIdList></Reference><Reference><Citation>Arlet JB, de Luna G, Khimoud D, Odièvre MH, de Montalembert M, Joseph L, et al. Prognosis of patients with sickle cell disease and COVID-19: a French experience. Lancet Haematol. (2020) 7(9):e632–4. Published correction appears in Lancet Haematol. 2020 Sep;7(9):e635. doi: 10.1016/S2352-3026(20)30256-8. 10.1016/S2352-3026(20)30204-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(20)30204-0</ArticleId><ArticleId IdType="pmc">PMC7302791</ArticleId><ArticleId IdType="pubmed">32563282</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin OY, Darbari DS, Margulies S, Nickel RS, Leonard A, Speller-Brown B, et al. Clinical outcomes of children and adolescents with sickle cell disease and COVID-19 infection: a year in review at a metropolitan tertiary pediatric hospital. Front Med (Lausanne). (2023) 10:987194. 10.3389/fmed.2023.98719</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.98719</ArticleId><ArticleId IdType="pmc">PMC9982154</ArticleId><ArticleId IdType="pubmed">36873869</ArticleId></ArticleIdList></Reference><Reference><Citation>Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood. (2010) 115(26):5300–11. 10.1182/blood-2009-04-146852</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2009-04-146852</ArticleId><ArticleId IdType="pmc">PMC2902131</ArticleId><ArticleId IdType="pubmed">20223921</ArticleId></ArticleIdList></Reference><Reference><Citation>Guarda CC, Silveira-Mattos PSM, Yahouédéhou SCMA, Santiago RP, Aleluia MM, Figueiredo CVB, et al. Hydroxyurea alters circulating monocyte subsets and dampens its inflammatory potential in sickle cell anemia patients. Sci Rep. (2019) 9(1):14829. 10.1038/s41598-019-51339-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-51339-x</ArticleId><ArticleId IdType="pmc">PMC6794261</ArticleId><ArticleId IdType="pubmed">31616024</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladwin MT, Shelhamer JH, Ognibene FP, Pease-Fye ME, Nichols JS, Link B, et al. Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. Br J Haematol. (2002) 116(2):436–44. 10.1046/j.1365-2141.2002.03274.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2141.2002.03274.x</ArticleId><ArticleId IdType="pubmed">11841449</ArticleId></ArticleIdList></Reference><Reference><Citation>Minniti CP, Zaidi AU, Nouraie M, Manwani D, Crouch GD, Crouch AS, et al. Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection. Blood Adv. (2021) 5(1):207–15. 10.1182/bloodadvances.2020003456</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2020003456</ArticleId><ArticleId IdType="pmc">PMC7802524</ArticleId><ArticleId IdType="pubmed">33570644</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian W, Jiang W, Yao J, Nicholson CJ, Li RH, Sigurslid HH, et al. Predictors of mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis. J Med Virol. (2020) 92(10):1875–83. 10.1002/jmv.26050</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26050</ArticleId><ArticleId IdType="pmc">PMC7280666</ArticleId><ArticleId IdType="pubmed">32441789</ArticleId></ArticleIdList></Reference><Reference><Citation>Alotaibi MM. Sickle cell disease in Saudi Arabia: a challenge or not. J Epidemiol Glob Health. (2017) 7(2):99–101. 10.1016/j.jegh.2016.12.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jegh.2016.12.006</ArticleId><ArticleId IdType="pmc">PMC7320430</ArticleId><ArticleId IdType="pubmed">28253475</ArticleId></ArticleIdList></Reference><Reference><Citation>Castonguay M, Dakhallah N, Desroches J, Colaiacovo ML, Jimenez-Cortes C, Claveau AM, et al. COVID-19 and sickle cell disease in the province of Quebec, Canada: outcomes after two years of the pandemic. J Clin Med. (2022) 11(24):7361. 10.3390/jcm11247361</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11247361</ArticleId><ArticleId IdType="pmc">PMC9781039</ArticleId><ArticleId IdType="pubmed">36555978</ArticleId></ArticleIdList></Reference><Reference><Citation>Akinsheye I, Alsultan A, Solovieff N, Ngo D, Baldwin CT, Sebastiani B, et al. Fetal hemoglobin in sickle cell anemia. Blood. (2011) 118(1):19–27. 10.1182/blood-2011-03-325258/</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-03-325258/</ArticleId><ArticleId IdType="pmc">PMC3139383</ArticleId><ArticleId IdType="pubmed">21490337</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>